Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: There is limited information from large-scale prospective studies regarding the prediction of type 1 diabetes by specific types of pancreatic islet autoantibodies, either alone or in combination. Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes. RESEARCH DESIGN AND METHODS: Two cohorts were derived from the first screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial-Type 1 (DPT-1). Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin (micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type 1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but responded to questionnaires (n = 28,507, 2.4% ICA(+)). The other cohort (Trials) included DPT-1 participants (n = 528, 83.3% ICA(+)). RESULTS: In both cohorts autoantibody number was highly predictive of type 1 diabetes (P < 0.001). The Questionnaire cohort was used to assess prediction according to the type of autoantibody. As single autoantibodies, ICA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were similarly predictive of type 1 diabetes in proportional hazards models (P < 0.001 for all). However, no subjects with mIAA as single autoantibodies developed type 1 diabetes. As second autoantibodies, all except mIAA added significantly (P < 0.001) to the prediction of type 1 diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type 1 diabetes. CONCLUSIONS: The data indicate that the number of autoantibodies is predictive of type 1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies. Autoantibody number, type of autoantibody, and autoantibody titer must be carefully considered in planning prevention trials for type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (55,74,75).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (53,74,75).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIES
Bottazzo, G., Florin-Christensen, A., & Doniach, D. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90140-8 · Cited by 1,469 · cited 2×
“The number shown for each curve (1, 2) indicates the number of autoantibodies.”
BackgroundInsulin antibodies in insulin-dependent diabetics before insulin treatment
Palmer, J. P., Asplin, C. M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P. K., & Paquette, T. L. (1983) · Science · doi:10.1126/science.6362005 · Cited by 1,078
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Termination of Pregnancy on Psychiatric Grounds
(1964) · The Lancet · doi:10.1016/s0140-6736(64)92746-1 · Cited by 681
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Keele, G. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91022-2 · Cited by 499
EVIDENCE FOR A LONG PREDIABETIC PERIOD IN TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUS
Gorsuch, A. N., Lister, J., Dean, B. M., Spencer, K. M., Mcnally, J. M., Bottazzo, G. F., & Cudworth, A. G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92795-1 · Cited by 480
Grubin, C. E., Daniels, T., Toivola, B., Landin-Olsson, M., Hagopian, W. A., Li, L., Karlsen, A. E., Boel, E., Michelsen, B., & Lernmark, �. (1994) · Diabetologia · doi:10.1007/bf00408469 · Cited by 415 · cited 1×
“Labeled recombinant GAD65 and ICA512 autoantibodies were produced by in vitro transcription/ translation with differential labeling ([(3)H]GAD65 and [(35)S]ICA512) (8,13).”
MethodBingley, P. J., Christie, M. R., Bonifacio, E., Bonfanti, R., Shattock, M., Fonte, M.-T., Bottazzo, G.-F., & Gale, E. A. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1304 · Cited by 389
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationType 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
Self-citationKeenan, H. A., Sun, J. K., Levine, J., Doria, A., Aiello, L. P., Eisenbarth, G., Bonner-Weir, S., & King, G. L. (2010) · Diabetes · doi:10.2337/db10-0676 · Cited by 500
Self-citation2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
the TEDDY Study Group, Krischer, J. P., Lynch, K. F., Schatz, D. A., Ilonen, J., Lernmark, Å., Hagopian, W. A., Rewers, M. J., She, J.-X., Simell, O. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3514-y · Cited by 444
Self-citationHuang, L., & Tepaamorndech, S. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.008 · Cited by 343
“The presence of one or more autoantibodies is a predictive marker for progressing to T1D in young prediabetic subjects and a marker for disease progression in diagnosed T1D patients (Orban et al., 2009).”
BackgroundThe Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314
“This ability to use autoantibodies for predicting future cases of T1D has also been supported by several large natural history trials including the NIH TrialNet and TEDDYefforts, as well as in a number of general populationbased efforts (Miao et al. 2007; Orban et al. 2009; Knip et al. 2010b).”
BackgroundScreening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Sims, E. K., Besser, R. E. J., Dayan, C., Geno Rasmussen, C., Greenbaum, C., Griffin, K. J., Hagopian, W., Knip, M., Long, A. E., Martin, F., et al. (2022) · Diabetes · doi:10.2337/dbi20-0054 · Cited by 246
Self-citationType 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Campbell‐Thompson, M., Wasserfall, C., Kaddis, J., Albanese‐O'Neill, A., Staeva, T., Nierras, C., Moraski, J., Rowe, P., Gianani, R., Eisenbarth, G., et al. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2316 · Cited by 236
“autoantibodies (ZnT8A), have been utilized to identify those in this prodromal period [5,6].”
BackgroundSelf-citationSteck, A. K., Johnson, K., Barriga, K. J., Miao, D., Yu, L., Hutton, J. C., Eisenbarth, G. S., & Rewers, M. J. (2011) · Diabetes Care · doi:10.2337/dc10-2088 · Cited by 195
Self-citationSteck, A. K., Vehik, K., Bonifacio, E., Lernmark, A., Ziegler, A.-G., Hagopian, W. A., She, J., Simell, O., Akolkar, B., Krischer, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2426 · Cited by 185
Self-citationThe changing epidemiology of type 1 diabetes: why is it going through the roof?
Vehik, K., & Dabelea, D. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1141 · Cited by 175
“The Diabetes Prevention Trial – Type 1 recently confirmed in a large screening cohort that not only presence but also number of autoantibodies, type of autoantibody and titre are predictive for T1D risk [14].”
BackgroundGarcia-Contreras, M., Shah, S. H., Tamayo, A., Robbins, P. D., Golberg, R. B., Mendez, A. J., & Ricordi, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-05787-y · Cited by 165
Diagnosis and classification of autoimmune diabetes mellitus
Canivell, S., & Gomis, R. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.020 · Cited by 163
B cells in type 1 diabetes mellitus and diabetic kidney disease
Smith, M. J., Simmons, K. M., & Cambier, J. C. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.138 · Cited by 175
Role of Type 1 Diabetes–Associated SNPs on Risk of Autoantibody Positivity in the TEDDY Study
Törn, C., Hadley, D., Lee, H.-S., Hagopian, W., Lernmark, Å., Simell, O., Rewers, M., Ziegler, A., Schatz, D., Akolkar, B., et al. (2015) · Diabetes · doi:10.2337/db14-1497 · Cited by 151
Self-citationβ Cell death and dysfunction during type 1 diabetes development in at-risk individuals
Herold, K. C., Usmani-Brown, S., Ghazi, T., Lebastchi, J., Beam, C. A., Bellin, M. D., Ledizet, M., Sosenko, J. M., Krischer, J. P., & Palmer, J. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78142 · Cited by 140
Self-citationAutoimmune Markers in Diabetes
Winter, W. E., & Schatz, D. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148205 · Cited by 161
Self-citationKrischer, J. P., Liu, X., Lernmark, Å., Hagopian, W. A., Rewers, M. J., She, J.-X., Toppari, J., Ziegler, A.-G., Akolkar, B., & on behalf of the TEDDY Study Group (2017) · Diabetes · doi:10.2337/db17-0261 · Cited by 133
Self-citationPugliese, A., Yang, M., Kusmarteva, I., Heiple, T., Vendrame, F., Wasserfall, C., Rowe, P., Moraski, J. M., Ball, S., Jebson, L., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12097 · Cited by 132
“This is consistent with investigations of pancreas organ donors from Europe (based on examination of small tissue fragments) (45) and with the low risk of disease progression observed in prospective studies of relatives with a single islet autoantibody (46).”
ResultSelf-citationJacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05047-w · Cited by 133
“However, in the Diabetes Prevention Trial–Type 1 study, which showed a higher risk among those with >2 autoantibodies [19], individuals were screened for islet cell autoantibodies (ICA), which we excluded, and the autoantibody to ZnT8 had not been discovered at that time.”
ResultSelf-citationType 1 Diabetes: Current Concepts in Epidemiology, Pathophysiology, Clinical Care, and Research
Gan, M. J., Albanese-O’Neill, A., & Haller, M. J. (2012) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2012.07.002 · Cited by 159
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0425 · Cited by 123
Self-citationPrasad, S., Kohm, A. P., McMahon, J. S., Luo, X., & Miller, S. D. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.04.005 · Cited by 122
(2014) · Diabetes Care · doi:10.2337/dc15-s001 · Cited by 116
Fu, W., Wojtkiewicz, G. R., Weissleder, R., Benoist, C. O., & Mathis, D. J. (2012) · Nature Immunology · doi:10.1038/ni.2233 · Cited by 115
Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
Skyler, J. S., & Ricordi, C. (2011) · Diabetes · doi:10.2337/db10-1114 · Cited by 109
Self-citationImmune therapy in type 1 diabetes mellitus
Lernmark, Å., & Larsson, H. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.237 · Cited by 111
Yu, L., Boulware, D. C., Beam, C. A., Hutton, J. C., Wenzlau, J. M., Greenbaum, C. J., Bingley, P. J., Krischer, J. P., Sosenko, J. M., Skyler, J. S., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2081 · Cited by 104
Self-citationReversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study
Vehik, K., Lynch, K. F., Schatz, D. A., Akolkar, B., Hagopian, W., Rewers, M., She, J.-X., Simell, O., Toppari, J., Ziegler, A.-G., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0181 · Cited by 103
Self-citationIslet Autoantigens: Structure, Function, Localization, and Regulation
Arvan, P., Pietropaolo, M., Ostrov, D., & Rhodes, C. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007658 · Cited by 96
“Even before the process of T1D is first recognized clinically, islet-cell autoantibody responses also become detectable (Atkinson and Maclaren 1993)—indeed, onset of detectable islet autoantibodies can be used to predict the appearance of clinical T1D in otherwise healthy individuals (Orban et al. 2009).”
BackgroundZhu, M., Xu, K., Chen, Y., Gu, Y., Zhang, M., Luo, F., Liu, Y., Gu, W., Hu, J., Xu, H., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2023 · Cited by 100
Self-citationType 1 diabetes and polyglandular autoimmune syndrome: A review
Hansen, M. P., Matheis, N., & Kahaly, G. J. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.67 · Cited by 114
Marré, M. L., McGinty, J. W., Chow, I., DeNicola, M., Beck, N. W., Kent, S. C., Powers, A. C., Bottino, R., Harlan, D. M., Greenbaum, C. J., et al. (2018) · Diabetes · doi:10.2337/db17-1166 · Cited by 100
Immune Recognition of β-Cells: Neoepitopes as Key Players in the Loss of Tolerance
James, E. A., Pietropaolo, M., & Mamula, M. J. (2018) · Diabetes · doi:10.2337/dbi17-0030 · Cited by 101
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 93
Self-citationImmunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 106
“In the Diabetes Prevention Trial-Type 1 (DPT-1), individuals that tested positive for a single specificity autoantibody had approximately a 6% 5-year risk in developing type 1 diabetes, while those with four different autoantibodies had a greater than 60% 5-year risk in developing the condition (in young children, the…”
BackgroundMiao, D., Guyer, K. M., Dong, F., Jiang, L., Steck, A. K., Rewers, M., Eisenbarth, G. S., & Yu, L. (2013) · Diabetes · doi:10.2337/db13-0534 · Cited by 97
Self-citationDistinguishing Persistent Insulin Autoantibodies With Differential Risk
Yu, L., Miao, D., Scrimgeour, L. A., Johnson, K. C., Rewers, M., & Eisenbarth, G. S. (2011) · Diabetes · doi:10.2337/db11-0670 · Cited by 96
“It has been known for more than a decade that individuals expressing only a single islet autoantibody are at low risk, and for those relatives expressing only IAA from the Diabetes Prevention Trial study there was essentially no risk of progression to diabetes (0 of 407) (22).”
BackgroundSelf-citationPhillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E. E., Colhoun, H. M., Couper, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06205-5 · Cited by 136
Self-citationMichels, A. W., Zhang, L., Khadra, A., Kushner, J. A., REDONDO, M. J., & Pietropaolo, M. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12299 · Cited by 94
“Indeed, this was the strategy in the trial to prevent development of T1DM (DPT-1), which successfully predicted the development of diabetes in first degree relatives of T1DM patients (121).”
MethodVehik, K., Bonifacio, E., Lernmark, Å., Yu, L., Williams, A., Schatz, D., Rewers, M., She, J.-X., Toppari, J., Hagopian, W., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2547 · Cited by 87
Self-citationEstablished and emerging biomarkers for the prediction of type 1 diabetes: a systematic review
Watkins, R. A., Evans‐Molina, C., Blum, J. S., & DiMeglio, L. A. (2014) · Translational research · doi:10.1016/j.trsl.2014.02.004 · Cited by 101
Ziegler, A.-G., Pflueger, M., Winkler, C., Achenbach, P., Akolkar, B., Krischer, J. P., & Bonifacio, E. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.02.004 · Cited by 81
“In contrast to the TEDDY children, but similar to progression rates in previous studies [7,15,17,18], 50% progression to diabetes in the antibody-positive BABYDIAB children was 85 months (p 1⁄4 0.”
Self-citationSosenko, J. M., Skyler, J. S., Beam, C. A., Krischer, J. P., Greenbaum, C. J., Mahon, J., Rafkin, L. E., Matheson, D., Herold, K. C., Palmer, J. P., et al. (2013) · Diabetes · doi:10.2337/db13-0656 · Cited by 85
Self-citationT Cell Epitopes and Post-Translationally Modified Epitopes in Type 1 Diabetes
McGinty, J. W., Marré, M. L., Bajzik, V., Piganelli, J. D., & James, E. A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0657-7 · Cited by 77
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citationIntestinal permeability in type 1 diabetes: An updated comprehensive overview
Mønsted, M. Ø., Falck, N. D., Pedersen, K., Buschard, K., Holm, L. J., & Haupt‐Jorgensen, M. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102674 · Cited by 81
Role of inflammatory cells in pathophysiology and management of diabetic retinopathy
Kovoor, E. T., Chauhan, S. K., & Hajrasouliha, A. R. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.07.008 · Cited by 78
Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count
So, M., Speake, C., Steck, A. K., Lundgren, M., Colman, P. G., Palmer, J. P., Herold, K. C., & Greenbaum, C. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab013 · Cited by 80
Self-citationYu, L., Dong, F., Miao, D., Fouts, A., Wenzlau, J. M., & Steck, A. K. (2013) · Diabetes Care · doi:10.2337/dc12-2245 · Cited by 78
Self-citationPrediction and prevention of Type 1 diabetes mellitus
Zhang, L., & Eisenbarth, G. S. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00102.x · Cited by 82
“The clinical use of the original anti-CD3 (OKT3) monoclonal antibody has been limited by its induction of cytokine release syndrome with, in severe cases, pulmonary edema developing within hours of treatment.76 Two specific humanized FcR non-binding anti-CD3 antibodies, namely teplizumab and otelixizumab, have been in…”
BackgroundSelf-citationHowson, J. M. M., Stevens, H., Smyth, D. J., Walker, N. M., Chandler, K. A., Bingley, P. J., & Todd, J. A. (2011) · Diabetes · doi:10.2337/db11-0131 · Cited by 69
the Type 1 Diabetes TrialNet Study Group, Bingley, P. J., Boulware, D. C., & Krischer, J. P. (2016) · Diabetologia · doi:10.1007/s00125-015-3830-2 · Cited by 70
“…to a single islet autoantigen are five-to eightfold lower than this and that some children develop single autoantibodies for the first time in later childhood and adolescence [2, 3, 6 – 9], but the natural history and determinants of progression to diabetes in this group are less well understood.”
BackgroundSelf-citationSteck, A. K., Dong, F., Wong, R., Fouts, A., Liu, E., Romanos, J., Wijmenga, C., Norris, J. M., & Rewers, M. J. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12092 · Cited by 67
Bosi, E., Boulware, D. C., Becker, D. J., Buckner, J. H., Geyer, S. M., Gottlieb, P. A., Henderson, C., Kinderman, A., Sosenko, J. M., Steck, A. K., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00569 · Cited by 68
Self-citationMiao, D., Steck, A. K., Zhang, L., Guyer, K. M., Jiang, L., Armstrong, T., Muller, S. M., Krischer, J., Rewers, M., Yu, L., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0186 · Cited by 64
“Accordingly, previous studies showed that T1DM risk increases with greater number of iAbs even among subjects with multiple iAbs.(6,14) The higher risk of T1DM with increasing number of iAbs may also reflect faster progression to T1D or that subjects with more iAbs are closer to clinical T1DM.”
Self-citationVitamin D and diabetes: the odd couple
Belle, T. L. V., Gysemans, C. A., & Mathieu, C. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.07.002 · Cited by 75
Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair
Selvaraj, U. M., Poinsatte, K., Torres, V. O., Ortega, S. B., & Stowe, A. M. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0460-4 · Cited by 69
“tiate into plasma cells to produce autoantibodies against insulin and other pancreatic islet antigens [103, 104].”
BackgroundAdvances in the Prediction and Natural History of Type 1 Diabetes
Bonifacio, E., & Ziegler, A. G. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.007 · Cited by 61
Birth and coming of age of islet autoantibodies
Bonifacio, E. E., & Achenbach, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13360 · Cited by 66
Steck, A. K., Wong, R., Wagner, B., Johnson, K., Liu, E., Romanos, J., Wijmenga, C., Norris, J. M., Eisenbarth, G. S., & Rewers, M. J. (2012) · Diabetes · doi:10.2337/db11-1228 · Cited by 57
Self-citationRole of B Lymphocytes in the Pathogenesis of Type 1 Diabetes
Hinman, R. M., & Cambier, J. C. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0543-8 · Cited by 65
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Greenbaum, C., VanBuecken, D., & Lord, S. (2019) · Drugs · doi:10.1007/s40265-018-1035-y · Cited by 52
Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies
Leal‐Lopes, C., Velloso, F. J., Campopiano, J. C., Sogayar, M. C., & Correa, R. G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/284680 · Cited by 58
“The detection of related autoantibodies may be used to predict the emergence of the pathological condition in apparently healthy individuals [164].”
BackgroundBansal, V., Boehm, B. O., & Darvasi, A. (2018) · Diabetologia · doi:10.1007/s00125-018-4690-3 · Cited by 52
“Thirty-eight per cent of the individuals were positive for islet-cell autoantibodies against the 65 kDa isoform of GAD (GAD65), islet-cell antigen 512 or insulin, and were likely to have autoimmune type 1 diabetes [17].”
BackgroundGorus, F. K., Balti, E. V., Vermeulen, I., Demeester, S., Van Dalem, A., Costa, O., Dorchy, H., Tenoutasse, S., Mouraux, T., De Block, C., et al. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04675.x · Cited by 51
Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype
Patel, S., Ma, C. S., Fourlanos, S., & Greenfield, J. R. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.001 · Cited by 53
Wasserfall, C., Montgomery, E., Yu, L., Michels, A., Gianani, R., Pugliese, A., Nierras, C., Kaddis, J. S., Schatz, D. A., Bonifacio, E., et al. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12797 · Cited by 48
Self-citationImmunologic and Metabolic Biomarkers of -Cell Destruction in the Diagnosis of Type 1 Diabetes
Lebastchi, J., & Herold, K. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007708 · Cited by 57
“In younger individuals, the risk approaches even 90% within 7 years (Orban et al. 2009).”
BackgroundJacobsen, L. M., Larsson, H. E., Tamura, R. N., Vehik, K., Clasen, J., Sosenko, J., Hagopian, W. A., She, J., Steck, A. K., Rewers, M., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12812 · Cited by 48
Self-citationEndesfelder, D., zu Castell, W., Bonifacio, E. E., Rewers, M., Hagopian, W., She, J., Lernmark, Å., Toppari, J., Vehik, K., Williams, A. J. K., et al. (2018) · Diabetes · doi:10.2337/db18-0594 · Cited by 49
“In contrast to most published approaches (2,5-10,12,20), our proposed method does not require a priori definition of relevant autoantibody patterns or seroconversion ages but intrinsically groups children taking longitudinal characteristics into account.”
BackgroundResultInfluentialSelf-citationType 1 diabetes and associated autoimmune diseases
Frommer, L., & Kahaly, G. J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i11.527 · Cited by 52
Spanier, J. A., Sahli, N. L., Wilson, J. C., Martinov, T., Dileepan, T., Burrack, A. L., Finger, E. B., Blazar, B. R., Michels, A. W., Moran, A., et al. (2017) · Diabetes · doi:10.2337/db17-0666 · Cited by 47
“Of the non-diabetic controls, we considered 2 of 26 pre-diabetic risk based on islet autoantibody positivity [16], however, DQ8 presence has potential elevated T1D genetic risk.”
BackgroundWilliams, A. J. K., Lampasona, V., Schlosser, M., Mueller, P. W., Pittman, D. L., Winter, W. E., Akolkar, B., Wyatt, R., Brigatti, C., Krause, S., et al. (2015) · Diabetes · doi:10.2337/db14-1693 · Cited by 46
“Median displacement of GADA binding in all 8 sera was 60% (range 39% to 78%) with 35 SGAD65(1-585) and 72% (range 70% to 76%) in the three sera found positive with 35 S-”
InfluentialNew Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation
Pugliese, A., Vendrame, F., Reijonen, H., Atkinson, M. A., Campbell-Thompson, M., & Burke, G. W. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0530-0 · Cited by 45
Xu, P., Krischer, J. P., & on behalf of the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2292 · Cited by 49
Self-citationStrollo, R., Vinci, C., Napoli, N., Pozzilli, P., Ludvigsson, J., & Nissim, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4296-1 · Cited by 47
Yang, J., James, E. A., Sanda, S., Greenbaum, C., & Kwok, W. W. (2013) · Immunology · doi:10.1111/imm.12034 · Cited by 44
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances
Mukherjee, N., Lin, L., Contreras, C., & Templin, A. T. (2021) · Metabolites · doi:10.3390/metabo11110796 · Cited by 49
Andersson, C., Kolmodin, M., Ivarsson, S.-A., Carlsson, A., Forsander, G., Lindblad, B., Ludvigsson, J., Kockum, I., Marcus, C., Samuelsson, U., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12093 · Cited by 44
“Nevertheless, measurement of ICA in children already identified as positive by one of the other antigen-specific autoantibodies might be valuable in assessing the risk, since the risk for developing type 1 diabetes mellitus is increased to 9% if two autoantibodies are identified among subjects from the general populat…”
BackgroundInfluentialPredicting Adult-Onset Autoimmune Diabetes
Leslie, R. D. (2010) · Diabetes · doi:10.2337/db09-1620 · Cited by 44
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Beam, C. A., Boulware, D. C., Greenbaum, C. J., Rafkin, L. E., Cowie, C., Cuthbertson, D., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0011 · Cited by 44
Self-citationAutoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody–Positive Individuals
So, M., O’Rourke, C., Bahnson, H. T., Greenbaum, C. J., & Speake, C. (2020) · Diabetes Care · doi:10.2337/dc19-1731 · Cited by 44
B cells and type 1 diabetes …in mice and men
Hinman, R. M., Smith, M. J., & Cambier, J. C. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.01.010 · Cited by 49
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Cuthbertson, D. D., Yu, L., Schatz, D., Orban, T., Eisenbarth, G. S., & Groups, D. P. T. 1. A. T. 1. D. T. S. (2011) · Diabetes Care · doi:10.2337/dc11-0981 · Cited by 42
Self-citationAn Overview of Organ-Specific Autoimmune Diseases Including Immunotherapy
Mastrandrea, L. D. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1099409 · Cited by 40
“The Diabetes Prevention Trial screened large numbers of at-risk individuals for serologic presence of autoantibodies (Orban et al., 2009).”
Predictors of slow progression to diabetes in children with multiple islet autoantibodies
Steck, A. K., Dong, F., Waugh, K., Frohnert, B. I., Yu, L., Norris, J. M., & Rewers, M. J. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.010 · Cited by 40
“Multiple islet autoantibodies are present in the great majority of prediabetics (1-3).”
BackgroundSelf-citation
Metadata
- Authors
- Orban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., & for the Diabetes Prevention Trial–Type 1 Study Group
- Affiliations
- Joslin Diabetes Center (US)
- University of Miami (US)
- University of South Florida (US)
- Barbara Davis Center for Childhood Diabetes, Denver, Colorado;
- University of Washington (US)
- University of Florida Health (US)
- Corresponding author
- Sosenko, Jay M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-09-09
- Volume
- 32
- Issue
- 12
- Pages
- 2269-2274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2782989
- OpenAlex
- W2164736991
- Cited by
- 260
- References
- 31
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 9 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 9 · 2019: 18 · 2018: 11 · 2017: 14 · 2016: 20 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 25
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Joslin Diabetes Center
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, GAD65 antibodies, autoantibody titers, diabetes prediction, prevention trials
- MeSH terms
- Autoantibodies, Diabetes Mellitus, Type 1, Glutamate Decarboxylase, Humans, Islets of Langerhans, Predictive Value of Tests, Prospective Studies, Surveys and Questionnaires, Cohort Studies, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.